Psychocardiological disorder and brain serotonin after comorbid myocardial infarction and depression: an experimental study

References

• Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290(7):898–904.10.1001/jama.290.7.898
   PubMed Web of Science ®Google Scholar
• Soufer R, Jain H, Yoon AJ. Heart-brain interactions in mental stress-induced myocardial ischemia. Curr Cardiol Rep. 2009;11(2):133–140.10.1007/s11886-009-0020-1
   PubMedGoogle Scholar
• Sanner JE, Frazier L, Udtha M. The role of platelet serotonin and depression in the acute coronary syndrome population. Yale J Biol Med. 2013;86(1):5–13.
   PubMedGoogle Scholar
• Roose SP, Spatz E. Treating depression in patients with ischaemic heart disease. Drug Saf. 1999;20(5):459–465.10.2165/00002018-199920050-00006
   PubMed Web of Science ®Google Scholar
• Liu MY, Ren YP, Zhang LJ, et al. Pretreatment with ginseng fruit saponins affects serotonin expression in an experimental comorbidity model of myocardial infarction and depression. Aging Dis. 2016;7(6):680–686.10.14336/AD.2016.0729
   PubMed Web of Science ®Google Scholar
• He DF, Ren YP, Liu MY. Effects of ginseng fruit saponins on serotonin system in sprague-dawley rats with myocardial infarction, depression, and myocardial infarction complicated with depression. Chin Med J. 2016;129(24):2913–2919.
   PubMed Web of Science ®Google Scholar
• Liu MY, Zhang LJ. Impact of trimetazidine pre-treatment on 5-hydroxytryptamine and serotonin transporter in rats with experimental myocardial infarction and depression. Zhonghua Xin Xue Guan Bing Za Zhi. 2017;45(2):137–141.
   PubMedGoogle Scholar
• Neki NS, Singh RB, Rastogi SS. How brain influences neuro-cardiovascular dysfunction. J Assoc Physicians India. 2004;52(52):223–230.
   PubMedGoogle Scholar
• Hornung JP. The human raphe nuclei and the serotonergic system. J Chem Neuroanat. 2003;26(4):331–343.10.1016/j.jchemneu.2003.10.002
   PubMed Web of Science ®Google Scholar
• Ramage AG, Villalon CM. 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci. 2008;29(9):472–481.10.1016/j.tips.2008.06.009
   PubMed Web of Science ®Google Scholar
• Tiradentes RV, Pires JG, Silva NF, et al. Effects of acute administration of selective serotonin reuptake inhibitors on sympathetic nerve activity. Braz J Med Biol Res. 2014;47(7):554–559.10.1590/1414-431X20143698
   PubMed Web of Science ®Google Scholar
• Hirano K, Kimura R, Sugimoto Y, et al. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol. 2005;144(5):695–702.10.1038/sj.bjp.0706108
   PubMed Web of Science ®Google Scholar
• Jiang W, Krishnan RR. Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease? Curr Psychiatry Rep. 2004;6(3):202–209.10.1007/s11920-004-0065-1
   PubMedGoogle Scholar
• Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the sertraline antidepressant heart attack randomized trial (SADHART) platelet substudy. Circulation 2003;108(8):939–944.10.1161/01.CIR.0000085163.21752.0A
   PubMed Web of Science ®Google Scholar
• Li Y, Wang D, Hu C, et al. Efficacy and safety of adjunctive trimetazidine therapy for acute myocardial infarction: a systematic review and meta-analysis. Cardiology 2016;135(3):188–195.10.1159/000446640
   PubMed Web of Science ®Google Scholar
• Zhang N, Lei J, Liu Q, et al. The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and meta-analysis. Cardiology 2015;131(2):86–96.10.1159/000375289
   PubMed Web of Science ®Google Scholar
• Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2000;86(5):580–588.10.1161/01.RES.86.5.580
   PubMed Web of Science ®Google Scholar
• Kay L, Finelli C, Aussedat J, et al. Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: effects on the energy state and mitochondrial function. Am J Cardiol. 1995;76(6):45B–49B.10.1016/S0002-9149(99)80462-7
   PubMed Web of Science ®Google Scholar
• Dehina L, Vaillant F, Tabib A, et al. Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(3):205–215.10.1007/s00210-012-0826-z
   PubMed Web of Science ®Google Scholar
• Shirahase H, Suzuki Y, Osumi S, et al. Inhibitory effects of trimetazidine dihydrochloride on aggregation, serotonin release and malondialdehyde production in rabbit platelets. Jpn J Pharmacol. 1988;47(1):29–34.10.1254/jjp.47.29
   PubMedGoogle Scholar
• Liu MY, Zhang LJ. Effects of trimetazidine, a myocardial metabolism agent, on regulating 5-hydroxytrytamine system of rats with myocardial infarction and/or depression. Zhong Hua Nei Ke Za Zhi. 2018;57(1). DOI:10.3760/cma.j.issn.0578-1426.2017.12.00
   Google Scholar
• Akbay E, Onur M. A new modified myocardial infarction animal model. J Cardiovasc Surg. 2013;1(3):69–71.10.5455/jcvs.
   Google Scholar
• Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266(5604):730–732.10.1038/266730a0
   PubMed Web of Science ®Google Scholar
• Hascoët M, Bourin M. The forced swimming test in mice: a suitable model to study antidepressants. In: Mood and anxiety related phenotypes in mice. Totowa, NJ: Humana Press; 2009. p. 85–118.10.1007/978-1-60761-303-9
   Google Scholar
• Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 1995 Sep;121(1):66–72.10.1007/BF02245592
   PubMed Web of Science ®Google Scholar
• Immuno-Biological Laboratories. Instructions for use: serotonin ELISA. IB89546[DB/OL]. [2016-01-08]. http://www.iblamerica.com/pdf/elisa/IB89546.pdf
   Google Scholar
• Celada P, Martín F, Artigas F. Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci. 1994;55(15):1237–1243.10.1016/0024-3205(94)00663-6
   PubMed Web of Science ®Google Scholar
• Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 1983;305(5935):627–630.10.1038/305627a0
   PubMed Web of Science ®Google Scholar
• Hillis LD, Lange RA. Serotonin and acute ischemic heart disease. N Engl J Med. 1991;324(10):688–690.10.1056/NEJM199103073241008
   PubMed Web of Science ®Google Scholar
• Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol. 2001;52(2):179–184.10.1046/j.0306-5251.2001.01426.x
   PubMed Web of Science ®Google Scholar
• Shimbo D, Child J, Davidson K, et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol. 2002;89(3):331–333.10.1016/S0002-9149(01)02236-6
   PubMed Web of Science ®Google Scholar
• Bianchi M, Moser C, Lazzarini C, et al. Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes. Exp Brain Res. 2002;143(2):191–197.10.1007/s00221-001-0979-3
   PubMed Web of Science ®Google Scholar
• Bulat M, Supek Z. Passage of 5-hydroxytryptamine through the blood-brain barrier, its metabolism in the brain and elimination of 5-hydroxyindo-leacetic acid from the brain tissue. J Neurochem. 1968;15(5):383–389.10.1111/jnc.1968.15.issue-5
   PubMed Web of Science ®Google Scholar
• Young LW, Darios ES, Watts SW. An immunohistochemical analysis of SERT in the blood–brain barrier of the male rat brain. Histochem Cell Biol. 2015;144(4):321–329.10.1007/s00418-015-1343-1
   PubMed Web of Science ®Google Scholar
• Brust P, Friedrich A, Krizbai IA, et al. Functional expression of the serotonin transporter in immortalized rat brain microvessel endothelial cells. J Neurochem. 2000;74(3):1241–1248.10.1046/j.1471-4159.2000.741241.x
   PubMed Web of Science ®Google Scholar
• Nakatani Y, Sato-Suzuki I, Tsujino N, et al. Augmented brain 5-HT crosses the blood–brain barrier through the 5-HT transporter in rat. Eur J Neurosci. 2008;27(9):2466–2472.10.1111/j.1460-9568.2008.06201.x
   PubMed Web of Science ®Google Scholar
• Sharma HS, Olsson Y, Kumar Dey PK. Changes in blood-brain barrier and cerebral blood flow following elevation of circulating serotonin level in anesthetized rats. Brain Res. 1990;517(1–2):215–223.10.1016/0006-8993(90)91029-G
   PubMed Web of Science ®Google Scholar
• Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: an overview. Neurobiol Dis. 2004;16(1):1–13.10.1016/j.nbd.2003.12.016
   PubMed Web of Science ®Google Scholar
• Ruggiero M, Zimmerman TP, Lapetina EG. ATP depletion in human platelets caused by permeabilization with saponin does not prevent serotonin secretion induced by collagen. Biochem Biophys Res Commun. 1985;131(2):620–627.10.1016/0006-291X(85)91282-3
   PubMed Web of Science ®Google Scholar
• Born GV, Gillson RE. Studies on the uptake of 5-hydroxytryptamine by blood platelets. J Physiol. 1959;146(3):472–491.10.1113/jphysiol.1959.sp006206
   PubMed Web of Science ®Google Scholar
• Dan AK, Iii MC, Neighoff JB, et al. Platelet response to serotonin in patients with stable coronary heart disease. Am J Cardiol. 2014;114(2):181–186.
   PubMed Web of Science ®Google Scholar
• Nowak P, Zagził T, Konecki J, et al. Trimetazidine increases [3H]glucose uptake in rat brain. Pharmacol Rep. 2006;58(4):559–561.
   PubMed Web of Science ®Google Scholar